Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-001-9
CAS number: 7783-49-5
Repeated dose toxicity data are not
available for zinc difluoride. However, studies conducted with soluble zinc
and fluoride substances were included in the dossier. For information please
refer to the endpoint discussion for zinc and fluoride.
endpoints for the human health hazard assessment are addressed by
read-across, using a combination of data on the fluoride moiety and the
zinc moiety (or one of its readily soluble salts). This way forward is
acceptable, since zinc difluoride dissociates to the fluoride anion and
the zinc cation upon dissolution in aqueous media.
the individual constituents of zinc difluoride become bioavailable (i.e.
in the acidic environment in the gastric passage or after phagocytosis
by pulmonary macrophages), the “overall” toxicity of the dissociated
substance can be described by the toxicity of the “individual”
constituents. Since synergistic effects are not expected, the human
health hazard assessment consists of an individual assessment of the
zinc cation and the fluoride anion.
detailed information on read-across can be found in IUCLID 0 "category".
administration of zinc oxide at a dose level of 40 mg/kg bw/day for a
period of 120 days in the diet of Sprague-Dawley female rats did not
lead to any noticeable clinical toxicity. In the high zinc groups a
significant elevation of serum cholesterol was observed as the only
biologically relevant effect which was independent from the vitamin A
co-administration (SCCNFP, 2003). Apart from animal studies a series
of human experimental studies have also been published. The following
reports confirm safe exposure levels in humans: In a double-blind trial,
13 humans received 200 mg zinc sulphate (corresponding to about 1.35 mg
Zn-ion) three times a day for 18 weeks, while 14 humans received a
placebo. No signs of toxicity associated with the zinc treatment were
reported (Hallbook & Lanner, 1972). In a study of Greaves and Skillen
also no toxicity was seen in 18 humans after administration of 220 mg
zinc sulphate (about 150 mg Zn-ion) 3 times a day for 16-26 weeks
(SCCNFP, 2003). Based on human studies the SCF established a no
observed adverse effect level (NOAEL) of 50 mg/person per day for zinc,
and this was subsequently confirmed by EFSA in 2006 and 2014 (EC, 2003;
EFSA Scientific Committee and NDA Panel, 2006; EFSA NDA Panel, 2014).
The NOAEL of 50 mg/person per day is based on the absence of any adverse
effects on a wide range of relevant indicators of copper status (as the
critical endpoint) in the studies by Davis et al. (2000), Milne et al.
(2001) and Bonham et al. (2003a, b) (EFSA CEF Panel, 2016).
of excessive exposure to fluorides on the skeletal system have been
identified as the most sensitive endpoint. Effects include reduced bone
strength, increase risk of fractures and/or skeletal fluorosis
(stiffness of joints, skeletal deformities). For quite some time, the
occupational exposure limit value for fluorides was set at 2.5 mg F/m³,
e.g. SCOEL (1998), as supported by the findings by Derrberry et al.
(1963) and Kaltreider et al. (1972). These authors had not reported
effects on the skeletal system for workers exposed for 10 years to an
average of 2.4 or 2.65 mg F/m³.
other and partly more recent human and animal data suggest that a limit
value of 2.5 mg F/m³ may not be sufficient to protect humans against
effects on the skeletal system: Assuming full absorption, and a
shift-breathing volume of 10 m³ (per 8-hours), a worker working in an
atmosphere containing 2.5 mg F/m³ would absorb 25 mg F/day. Further, as
summarised above, the additional background fluoride intake from food,
drinking water and dental care products may add up to a couple of mg
F/day or even over 6 mg F/day in worst case scenarios, thus leading to
worst case estimates of combined exposure of more than 30 mg F/day.
contrast, according to US DHHS (1991) and WHO (2002), skeletal fluorosis
(clinical phase III) may result when exposed to 20 mg F/day for more
than 20 years.
sources support the conclusion that a safe total daily intake of
fluoride should at least be below ca. 14 mg F/day.
EPA (1985) reported no skeletal fluorosis when fluoride in drinking
waters was 4 mg F/L (i.e. ca. 8 mg F/day assuming a consumption of 2
The study by Li et al (2001) suggested no increased risk for bone
fractures over 20 years at up to7.85 mg F/day, but increased risk for
humans exposed to 14.13 mg F/day.
The study by Hillier et al. (2000) in which no increase in the
prevalence of hip fractures was seen at 0.2 - 0.3 mg F/day is supportive.
The animal study by Turner et al. (2001) suggested a NOAEL for effects
on bone density of 0.94 mg F/kgbw/day with a LOAEL at 3.2 mg F/kgbw/day.
According to the authors, the NOAEL and LOAEL found in the rat study
correspond to drinking waters concentrations for humans of 3 mg F/L and
10 mg F/L, respectively. Assuming a water intake of 2 L/day, these can
be converted to corresponding daily doses of 6 mg F/day (NOAEL) and 20
mg F/day (LOAEL). Further, assuming a 10 m³ inhalation volume (for an 8
hour shift), these correspond to 0.6 mg F/m³ (NOAEC) and 2 mg F/m³
on these considerations, a workplace exposure limit (i.e. the DNEL) is
derived at 1 mg F/m³. As a worst case assumption, 100% systemic
absorption may be assumed, which together with a 10 m³ shift breathing
volume results in an estimated maximum daily dose at the workplace of 10
mg F/day. Note: it appears unrealistic to assume that a worker spends a
full 8-hour shift in an atmosphere containing 1 mg F/m³. Further,
depending for example on the particle size, not all particles will be
inhaled (some will not be inhaled at all, others will be exhaled). On
the other hand, there may be some contribution of fluorides absorbed via
the skin (dermal exposure), or also of inadvertent ingestion
(hand-to-mouth transfer). Whereas the latter cannot be quantified
reliably and whereas such additional dermal and oral exposure would be
expected on under circumstances of poor industrial hygiene, a 100% total
systemic absorption is maintained, still presenting a conservative
scenario for the risk assessment. Acknowledging that background intake
due to drinking water, food, dental care products etc. may exceed 5-6 mg
F/day in highly worst case scenarios, a typical background intake would
rather be in the of range of 0.5-2 mg F/day. Adding a worst case
workplace exposure of 10 mg/day and a typical background exposure of 2
mg/day will still result in a safe total fluoride intake for workers.
the DNEL of 1 mg F/m³ is adequately protective, even when considering
that workers can - in addition to the inhalation route - be further
exposed to fluorides via other routes, i.e. dermal and/or oral
(hand-to-mouth-transfer) at the workplace, and also due to a background
intake via diet, drinking water and dental care products.
on the results described above, classification for repeated dose
toxicity is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again